SAB Biotherapeutics

Company snapshot

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the gl

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SAB Biotherapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for SAB Biotherapeutics.

1. Jun 8, 2026 Clinical update

   SAB-142, SODIUM CHLORIDE — Phase 2

2. Jun 8, 2026 Clinical update

   Single Ascending Dose of SAB-176 — Phase 1

3. Jun 8, 2026 Clinical update

   bamlanivimab 7000mg — Phase 3

4. Jun 8, 2026 Clinical update

   SAB-185 — Phase 1

5. Jun 5, 2026 Clinical update

   SAB-176 — Phase 1

View all clinical trial activity →

• What is SAB Biotherapeutics?

  SAB Biotherapeutics is a biotech organization headquartered in Gaithersburg, USA. It trades on NYSE under ticker SABS. Primary therapeutic focus areas include Type 1 Diabetes, Coronavirus, Influenza A H1N1, Influenza Type A, COVID-19. NovaPharmaNews links 8 clinical program(s), 0

• Is SAB Biotherapeutics publicly traded?

  Yes. SAB Biotherapeutics is listed with ticker SABS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SAB Biotherapeutics develop or market?

  We link 10 drug profile(s) where SAB Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sab-biotherapeutics#company-drugs.

• What are the latest developments for SAB Biotherapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SAB Biotherapeutics focus on?

  SAB Biotherapeutics focuses on Type 1 Diabetes, Coronavirus, Influenza A H1N1 based on our analysis of their pipeline programs and drug development activities.